QQQ0.76%

Trending

TSLA6.65%

Info

home Symbol VNDAnews

Exchange: NASDAQ·Updated 07:15 AM EDT

VNDAVanda Pharmaceuticals Inc

$5.40

$0.05

(0.94%)

Pre-Market

Prev Close $5.35

EarningsJul 29

Mkt Cap$329.54M

Vol523.00

News

all

press releases

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab...

PR Newswire

More News

NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment PR Newswire WASHINGTON, July 15, 2026 WASHINGTON, July...

PR Newswire

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit PR Newswire WASHINGTON, July 10, 2026 WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda...

PR Newswire

VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy

The designation covers VCA-894A, Vanda’s investigational treatment for Charcot-Marie-Tooth disease type 2S.

Stocktwits

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S PR Newswire...

PR Newswire

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis PR Newswire WASHINGTON, May 27, 2026 WASHINGTON, May 27, 2026...

PR Newswire

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences PR Newswire WASHINGTON, May 7, 2026...

PR Newswire

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -54.72% and -9.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks

Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative return on equity of 23.85...

MarketBeat

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results PR Newswire WASHINGTON, May 6, 2026 Fanapt net product sales rose...

PR Newswire

...

Advertisement|Remove ads.